Servier agreed to acquire Day One Biopharmaceuticals in an all-cash transaction valued at approximately $2.5 billion.
The offer price is set at $21.50 per share. This represents a 68% premium over the company's recent valuation. The premium is calculated against the closing price on March 5, 2026. Day One’s board of directors unanimously recommended that shareholders tender their shares.
The acquisition advances Servier’s strategy to expand its presence in rare oncology and pediatric cancers. The deal grants Servier control of Ojemda, an approved therapy for pediatric brain tumors. Ojemda generated significant revenue throughout 2025.
The transaction is expected to close in the second quarter of 2026. The deal remains subject to regulatory approval.